ArQule Compounds Sample Clauses

The "ArQule Compounds" clause defines the specific chemical compounds that are owned, developed, or controlled by ArQule and are subject to the terms of the agreement. This clause typically lists or references the compounds by name, code, or chemical structure, and may include any derivatives, analogs, or improvements thereof. By clearly identifying which compounds are covered, the clause ensures that both parties understand the scope of their rights and obligations, thereby preventing disputes over which substances are included in the collaboration or licensing arrangement.
ArQule Compounds. ArQule shall have sole control, at its expense, over the preparation, filing, prosecution, issuance, maintenance, extension, enforcement and/or defense of any ArQule Patent Rights in or relating to ArQule Compounds; provided that ArQule shall use commercially reasonable efforts to consult with Abbo▇▇ ▇▇▇or to any deadline or action with the PTO or any foreign patent office, and to furnish Abbo▇▇ ▇▇▇h copies of all relevant documents in advance of such consultation. Abbo▇▇ ▇▇▇ll have sole control, at its expense, over the preparation, filing, prosecution, issuance, maintenance, extension, enforcement and/or defense of any Joint Patent Rights in or relating to ArQule Compounds; provided that Abbo▇▇ ▇▇▇ll use commercially reasonable efforts to consult with ArQule prior to any deadline or action with the PTO or any foreign patent office, and to furnish ArQule with copies of all relevant documents in advance of such consultation. Abbo▇▇ ▇▇▇ll have control, at its expense, over the preparation, filing, prosecution, issuance, maintenance, extension, enforcement and/or defense of any Abbo▇▇ ▇▇▇ent Rights in or relating to ArQule Compounds.
View SourceView Similar (2)
ArQule Compounds. At any time during the Screening Phase, SB will provide a list of Licensed Compound Sets with ***** activity to the JSC for consideration as lead optimization projects. The JSC will select one of these Licensed Compound Sets for optimization by ArQule under this Agreement. ArQule shall commence work on this project promptly after the JSC develops and approves a workplan.
View SourceView Similar (2)
ArQule Compounds. ArQule Derivative Compounds 7. Intellectual Property Rights 7.1. Ownership of Patent Rights 7.2. Management of Joint Patent Rights 7.3. Cooperation of the Parties 7.
View Source
ArQule Compounds. All ArQule Compounds are owned by ArQule except, and only to the extent that, Solvay Duphar can show that any such compound was in the possession of Solvay Duphar before it was provided by ArQule to Solvay Duphar or its Affiliates.
View Source

Related to ArQule Compounds

  • Licensed Product The term “Licensed Product” shall mean any product (a) the manufacture, use, importation, sale or offer for sale of which would, in the absence of the license granted by this Agreement, infringe a Valid Claim of any of the Licensed Patent Rights, or (b) that is comprised of, utilizes or incorporates Licensed Biological Materials, or (c) that is discovered, developed or made using a Licensed Process.

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.

  • Licensed Products Lessee will obtain no title to Licensed Products which will at all times remain the property of the owner of the Licensed Products. A license from the owner may be required and it is Lessee's responsibility to obtain any required license before the use of the Licensed Products. Lessee agrees to treat the Licensed Products as confidential information of the owner, to observe all copyright restrictions, and not to reproduce or sell the Licensed Products.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Research Collaboration Upon FibroGen’s request, the Parties will discuss conducting a research program funded by AstraZeneca and directed toward franchise enhancement and lifecycle management for HIF Compounds or other topics that the Parties determine relevant to the Products and the Field. Upon agreement on the terms of such research program, the Parties will enter into a separate agreement or amend this Agreement accordingly.